Why a New Drug Just Entered the Market With a List Price One-Tenth of Its Rival

And a Health Affairs Forefront piece brings much-needed clarity to the 340B rebate model conversation

Nov 19, 2025

Subscribe to Cost Curve Apex to read the rest.

Upgrade to Apex to get access to this post and other subscriber-only content.

No posts found